Abstract Background: Breast cancer cells with tumor-initiating capabilities (BSCs) are considered to maintain tumor growth and govern metastasis. Hence, targeting BSCs will be crucial to achieve successful treatment of breast cancer. Methods: We characterized mammospheres derived from more than 40 cancer patients and two breast cancer cell lines for the expression of estrogen receptors (ERs) and stem cell markers. Mammosphere formation and proliferation assays were performed on cells from 19 cancer patients and five healthy individuals after incubation with ER-subtype selective ligands. Transcriptional analysis was performed to identify pathways activated in ERb-stimulated mammospheres and verified using in vitro experiments. Xenograft models (n ¼ 4 or 5 per group) were used to study the role of ERs during tumorigenesis. Results: We identified an absence of ERa but upregulation of ERb in BSCs associated with phenotypic stem cell markers and responsible for the proliferative role of estrogens. Knockdown of ERb caused a reduction of mammosphere formation in cell lines and in patient-derived cancer cells (40.7%, 26.8%, and 39.1%, respectively). Gene set enrichment analysis identified glycolysis-related pathways (false discovery rate < 0.001) upregulated in ERb-activated mammospheres. We observed that tamoxifen or fulvestrant alone was insufficient to block proliferation of patient-derived BSCs while this could be accomplished by a selective inhibitor of ERb (PHTPP; 53.7% in luminal and 45.5% in triple-negative breast cancers). Furthermore, PHTPP reduced tumor initiation in two patient-derived xenografts (75.9% and 59.1% reduction in tumor volume, respectively) and potentiated tamoxifen-mediated inhibition of tumor growth in MCF7 xenografts. Conclusion: We identify ERb as a mediator of estrogen action in BSCs and a novel target for endocrine therapy.
and activate estrogen response elements (ERE) in reporter gene assays (11) . Although considered ERa-negative, BSC and MSC numbers can be expanded by incubation with estradiol (12, 13) , previously explained by paracrine stimulation (14, 15) . To dissect the role of estrogen receptors within BSCs, we performed a comprehensive analysis of mammospheres generated from patientderived cancer cells and from normal benign breast epithelium.
Methods

Clinical Material
Between 2009 and 2015, fresh primary breast cancer specimens from 88 patients were collected at the Karolinska University Hospital. Biobanking was approved by the local biobank board and the Department of Pathology. Experimental procedures and protocols were approved by the regional ethics review board (Etikprö vningsn€ amnden) in Stockholm. Tumor tissues with corresponding clinical data were obtained after signed informed consent from each patient. Anonymized normal breast specimens from elective reduction mammoplasties at the Capio St Gö ran's Hospital, Stockholm, Sweden, were also used.
Mouse Experiments
All mouse experiments were approved by the local animal welfare board at Karolinska Institutet and in accordance with institution guidelines. Intact or ovariectomized SCID/NOD female mice three to eight weeks old were transplanted with MCF7 cells, MDA-MB-231 cells, or patient-derived breast tumor fragments HCI001 and HCI002 into the fourth mammary gland fat pad. Four or five mice per group were assigned to different treatment conditions according to the aims of each experiment. Exact numbers are given in the "Results" and in the figure legends. Detailed procedures are provided in the Supplementary Materials (available online).
Statistical Analyses
Two-tailed t test was used to test statistical significance in the assays, real-time quantitative polymerase chain reaction (qPCR) experiments, and mouse experiments. Tests were either paired or independent depending on experimental setup (paired or unpaired samples). Extreme outlier values of technical causes (<10% of samples per group) have been excluded from analysis. Kruskal-Wallis nonparametric test was used to compare the ERb protein expression between the molecular subtypes. Spearman's rank order correlation was used to test the association between ERb and ERa expression. A Pvalue equal to or less than .05 was considered statistically significant.
For detailed information on all other experimental methods, please see the Supplementary Materials (available online).
Results
Expression of ERb in Normal and Malignant Mammary Stem Cells
ERb protein expression in tumors was analyzed by immunohistochemistry in a cohort of 187 patients with available gene expression-based subclass categorization (16) . In contrast to ERa expression, concentrated within the luminal subtypes, the mean grading of ERb staining (P < .49) was not associated with any certain molecular subtype, and no correlation was found between the ERa mRNA and ERb protein expression profiles as assessed by Spearman rank correlation (P ¼ .98, q ¼ .0017) ( Figure 1A ; Supplementary Figure 1A , available online). Next, dual immunohistochemical staining with ERb and CD44 was performed, showing ERb protein expression in 79.2% of all breast tumors. In 71.0% of the tumors, ERb was detected within the CD44(þ) cell population ( Figure 1B) .
We further confirmed that patient-derived mammospheres were ERa(-) as described before (17), but we also observed a strong ERb nuclear positivity (>80.0% of mammospheres) ( Figure 1C) . Interestingly, BSCs from triple-negative breast cancers (ERa[-)]/PR[-]/Her2[-]), clinically considered estrogen independent, stained positive for ERb with similar intensity (three patients). We were able to prove that mammospheres were enriched for BSCs as the vast majority of mammospheres were CD44(þ)/CD24(-), ALDH1 High (>95.0%), and positive for PKH26 ( Figure 1C ), a marker for quiescence (18) . ERb was also co-expressed with CD44 or ALDH1 in 26 out of 26 tumors, as well as in the majority of EpCAM (4) and PKH26-positive mammospheres. To explore the potential role of ERb in MSCs, we analyzed ERb expression in mammopsheres from patients undergoing reduction mammoplasties. Similar to BSCs, MSCs (n ¼ 16 patients) were all ERa-negative and mostly ERb-positive and co-expressed CD44 and ALDH1 (Supplementary 
Impact of Altered ERb Expression on the Cancer Stem Cell Phenotype
To assess the importance of ERb for maintenance of the BSC state, we produced MCF7 cells with shRNA-mediated knockdown of ERb (Supplementary Figure 2 , A-C, available online), resulting in 40.7% reduction (P < .01) of mammosphere formation ( Figure 2A) . A similar effect was seen in MDA-MB-231 cells (26.8% reduction, P < .04) (Supplementary Figure 2E , available online). Importantly, cells without ERb overexpression could not maintain mammosphere formation after the sixth generation, whereas cells with ERb overexpression maintained their increased mammosphere-forming capacity throughout the experiment ( Figure 2B ). By forced differentiation of patient-derived BSCs in normal serum-containing medium, we observed a 70.0% and 60.0% reduction of cellular ERb and ALDH1 expression, respectively ( Figure 2C ), underscoring a tight connection between ERb expression and the stem cell state. To confirm our findings, ERb was knocked-down by lentiviral-mediated shRNA in patient-derived BSCs. Nuclear ERb expression was silenced in 60.0% to 85.0% of the mammosphere cells, and, as expected, ERb silencing in BSCs caused a profound decrease in total number of mammospheres (39.1% reduction, P ¼ .03) ( Figure 2D ). We observed that cells with silenced ERb also lost the expression of ALDH1 whereas CD44-intensity was unchanged, giving further support to the importance of ERb to maintain the BSC state ( Figure 2E ; Supplementary Figure 2D , available online). Figure 3A) . However, incubation with DPN increased the number of mammospheres from both cell lines compared with the vehicle controls (P ¼ .01 and P ¼ .005, respectively) ( Figure 3B ). This finding was also confirmed with patient-derived primary tumor cells, where incubation with DPN and E2 increased mammosphere numbers by 70.6% (P ¼ .008) and 67.7% (P ¼ .04), respectively ( Figure 3C ). This effect was corroborated by BrdU staining after similar incubations ( Figure 3D ). However, the ERa-selective agonist propylpyrazoletrisphenol (PPT) did not affect the number of mammospheres, nor did 4-hydroxytamoxifen (4OHT) or fulvestrant ( Figure 3C ). When the same treatments were applied to MSCs, stimulation of ERb by DPN caused a dramatic reduction (29.1%, P ¼ .01) in mammosphere formation, indicating that ERb is not proliferative in the MSC population ( Figure 3E ). In addition, treatment of MCF7 spheres with DPN increased embryonic stem cell gene expression, as well as of the ER-target genes PR and PS2 (23, 24) . In adherent cells, however, DPN treatment did not affect those genes, although PR was induced (Supplementary Figure 3 , available online). As a consequence of our findings, we hypothesize that a switch in ER dependence of cancer cells occurs in the adherent (differentiated) vs mammosphere (stem-like) state ( Figure 3F ).
Functional Role of ERb in Breast Cancer Stem Cells
To further explore ERb function in BSCs, we performed wholetranscriptome analysis of mammospheres (MCF7S) incubated with vehicle control or DPN. Seventy-five transcripts were differentially regulated upon DPN treatment compared with the control group (moderated t tests, nominal P < .001, false discovery rate [FDR] 0.15) (Supplementary Table 2 , available online). To assess the biological relevance of the distinct gene expression pattern, we performed gene set enrichment analyses (GSEA) of the canonical pathways gene set collection in the Molecular Signatures Database (Broad Institute). Seven gene sets were statistically significantly enriched in DPN-treated mammospheres compared with the control (FDR < 0.10) (Supplementary Table 2 , available online), with the majority related to glycolytic metabolism and with REACTOME_GLYCOLYSIS as top pathway (FDR < 0.001) ( Figure 4A ).
Furthermore, we detected the L-lactate releasing amount in MCF7S culture medium as an indicator of cellular glycolytic rate. We used the ERb-selective antagonist 4-[2-Phenyl-5,7bis (trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) to validate the specificity of DPN and to inhibit ERb function (25) . After incubation with DPN, L-lactate secretion increased statistically significantly (23.1% induction, P ¼ .02) compared with the control group, and this induction could be neutralized by cotreatment with PHTPP ( Figure 4B ). To confirm an ERb-mediated effect, we employed ERb-knockdown of MCF7 cells and performed the identical assay. The stimulation of the glycolytic shift could only be observed in the scrambled control supplied with DPN, but was absent in two knockdown clones after similar treatments ( Figure 4C ). To test the hypothesis on the clinical level, we generated patient-derived BSCs and observed increased L-lactate secretion in response to DPN from both patients (36.1% induction, P ¼ .006, and 86.7% induction, P ¼ .001) ( Figure 4D ). We also measured the oxygen consumption rate (OCR) after incubation with selective ER ligands. As expected, DPN stimulation in MCF7S undermined OCR. Accordingly, this metabolic phenotype can be overturned by PHTPP ( Figure 4E , upper panel). We further determined the mitochondrial function by evaluation of maximal respiration rates. Consequently, PHTPP treatment resulted in a favorable 2.7-fold elevation (P ¼ .007) of maximal respiratory capacity, while DPN treatment caused a two-fold decrease (P ¼ .04) compared with the control ( Figure 4E, lower panel) . Hence, suppressing ERb induces a substantial capacity for oxidative metabolism. Although the strongest OCR shift was observed in the first-generation mammospheres, there was a statistically nonsignificant but consistent trend of OCR changes retained in the third-generation mammospheres (Supplementary Figure 4A , available online). Together, our data suggest that the maintenance of the BSC phenotype relies on ERb-mediated shifting of glycolysis. We also investigated the expression levels of glycolysis key enzymes and the mitochondrial respiration complex in scrambled control MCF7S and ERb-knockdown MCF7S. We observed a 40. 0% induction (P < .001) of mitochondrial NADH:ubiquinone oxidoreductase core subunit 1 (MT-ND-1) in ERb knockdown-MCF7S and reduction of the majority of glycolytic enzymes (hexokinase 2-HK2, pyruvate kinase muscle 2-PKM2, and enolase 1-ENO1), although lactate dehydrogenase A (LDHA) mRNA was unchanged ( Figure 4F ). Again, when the comparisons were made within the scrambled control and ERb knockdown clone, respectively, the variations of all genes induced by DPN were higher when ERb was present ( Figure 4G ). Confocal microscopy after immunofluorencence staining of MCF7S wildtype and ERb-knockdown MCF7 implied that DPN stimulation of presented ERb could impair the quantity of mitochondria in the cells (Supplementary Figure 4 , B and C, available online). Together, our results suggest that stimulating ERb brings the BSCs pool toward glycolysis, partially because of the suppression of mitochondrial respiration and attenuation of mitochondrial biogenesis.
ERb and Breast Tumor Growth in Mouse Xenografts
To assess ERb's role in tumorigenesis, we transplanted adherent MCF7 cells into the mammary fat pad of ovariectomized NOD/ SCID-mice. In absence of ER ligands, tumors remained very small whereas daily injections with DPN caused a three-fold increase (P ¼ .03) in tumor volume after five weeks without any increase in uterus weight, commonly considered as an indicator of ERa activation. PPT treatment caused a six-fold increase (P ¼ .02) in tumor volume, most probably reflecting the low ERb/ERa ratio in differentiated MCF7 cells. However, the combination of PPT and DPN resulted in the largest tumor volumes (P ¼ .01) ( Figure 5A ; Supplementary Figure 5A , available online). We thereby conclude that both ER subtypes are important for tumor growth.
Next, we injected MCF7-derived mammospheres into the mammary fat pads of ovariectomized NOD/SCID mice. Treatment with E2 resulted in the largest tumors, reflecting the activation of both ERa and ERb during tumor progression (Supplementary Figure 5C , available online). DPN caused a sixfold induction (P ¼ .02) in tumor volume compared with the untreated control. Importantly, the E2-induced tumor volume was reduced by 43.3% (P ¼ .04) by cotreatment with PHTPP ( Figure 5B ; Supplementary Figure 5B , available online).
Again, to study the importance of ERb during tumor initiation within the triple-negative phenotype, we transplanted ARTICLE MDA-MB-231 cells with Tet-on inducible ERb shRNA into the intact NOD/SCID mice. Knockdown of ERb reduced the tumor volume by more than 50.0% (P ¼ .01) (confirmed in Supplementary  Figure 5 , E and F, available online ) compared with the scrambled control ( Figure 5C ; Supplementary Figure 5D , available online). Furthermore, we injected wild-type MDA-MB-231 cells into the intact NOD/SCID mice. By treating with PHTPP during tumor growth, we observed a reduction of tumor volume at the five-week end point, although statistically nonsignificant ( Figure 5D; Supplementary Figure 5G , available online).
As expected, in MCF7 mammosphere-derived xenografts, E2 treatment caused a nearly eight-time increase (P ¼ .001) in the number of mitotic cells compared with the untreated control, whereas PHTPP almost completely neutralized (P < .001) this effect ( Figure 5F ). Nearly 50.0% of the tumor cells in the untreated control group were positive for ALDH1, reflecting the high expression of ALDH1 in mammospheres ( Figure 5E, left panel) . The level of ALDH1
High cells was retained in the DPN-and E2-treated groups. Most interestingly, in tumors from the combined E2þPHTPP group, very few ALDH1 High cells were observed ( Figure 5E , right panel). This finding not only reflects a tumor-regressive effect by PHTPP but also indicates a potential to reduce BSCs numbers.
We then sought to further investigate the tumorsuppressive role of PHTPP by treating BSCs isolated from patients with luminal A (ERþ/PRþ/Her2-) and triple-negative (ER-/ PR-/Her2-) breast carcinomas ( Figure 5 , G and H). As described earlier, E2 or DPN consistently induced mammosphere formation (41.4%, P ¼ .02, and 22.6%, P ¼ .001, respectively), whereas cotreatment with PHTPP completely abolished this stimulatory effect of E2 (P ¼ .03) or DPN (P < .001). Moreover, PHTPP alone caused a statistically significant reduction of mammosphere numbers compared with the untreated control (53.7% reduction in Luminal tumors, P ¼ .04, and 45.5% reduction in TNBC tumors, P < .001). This further indicates that ERb is important for BSC maintenance and proliferation.
Targeted therapies for patients with triple-negative breast cancers (TNBCs) are lacking. Hence, to further investigate the possibility of targeting ERb, two triple-negative patient-derived xenografts (PDXs) expressing endogenous ERb (Supplementary Figure 5I , available online), HCI001 and HCI002, were established and assigned into different treatment groups. At end point, DPN treatment resulted in the largest tumor volumes in both models and PHTPP single treatment reduced tumor growth (P < .001 in HCI001) (Supplementary Figure 5H , available online). Moreover, when PHTPP was cosupplied, it could gradually neutralize the stimulatory effect of DPN on tumor growth (P ¼ .002 in HCI001) ( Figure 5, I-L) . This further indicates that targeting ERb is a possible therapeutic strategy in TNBCs.
Combining Tamoxifen With an ERb Antagonist in a Xenograft Model
We sought to evaluate whether a combination of tamoxifen and ERb modulator would be more efficient to block tumor growth as a consequence of ERb expression in BSCs. Orthotopically injected MCF7 cells were allowed to form palpable tumors in NOD/SCID mice. As expected, tamoxifen caused a dramatic inhibition of tumor growth but was unable to completely eliminate the tumor ( Figure 6A; Supplementary Figure 6 , available online). Combining tamoxifen with PHTPP caused a gradual decrease of tumor size with increasing concentration of PHTPP ( Figure 6B ), further indicating that PHTPP improves the response to tamoxifen.
Discussion
The current dogma of BSCs as more or less estrogen insensitive does not fully reflect the central importance of estrogens as key factors for tumor growth. Although ERa is exclusively expressed in the luminal breast cancer subtypes (30), the expression of ERa is completely negative in BSCs. In contrast, we found that ERb was expressed at similar levels within all breast cancer subtypes. ERb protein was identified in the majority of BSCs, but its expression declined as the BSCs differentiated. We also observed an increase of ERb mRNA upon mammosphere formation. Our findings are in line with an earlier study reporting elevated ERb expression in basal/stem cell populations (31) .
We investigated the molecular function of ERb in BSCs and observed a strong increase in sphere formation upon treatment with E2 or DPN. This effect was observed in repeated assays from patients with varying primary tumor characteristics. As a consequence of ERa absence, treatment with its agonist PPT did not affect the number of mammospheres, nor did tamoxifen or fulvestrant. We have recently shown that tamoxifen activates mean6 SD, n ¼ 4 mice/group, tumor take rate ¼ 100.0%). Doxycycline (2 mg/mL) was provided in the drinking water. D) Intact NOD/SCID mice were transplanted with 2 x10 6 MDA231 cells for control (vehicle) and PHTPP treatment groups (n ¼ 4 mice/group, tumor take rate ¼ 100.0%). The treatments were given by injections every second day. Tumors were resected at end point and tumor volume was calculated (Student's t test, mean 6 SD). E) Immunohistochemical staining of ALDH1 in MCF7 xenografts from Figure 5B . Because of the very small size of PHTPP-treated tumors, ALDH1-staining could not be performed. The left panel represents average values (0, 0.0%; 1, 1.0%-10.0%; 2, 10.0%-50.0%; 3, 50.0%-100.0%, positive cytoplasmic stained cells) (Student's t test, mean6 SD, n ¼ 3 counts). mTOR-regulated ribosomal synthesis and is insufficient to inhibit proliferation in BSCs (32) . Our findings shed light on the incapability of current endocrine agents to completely eradicate all tumor cells as a proportion of breast cancers relapse after or during adjuvant endocrine therapy. Breast cancer cell lines exhibit very low levels of ERb mRNA and are considered ERb-negative by many research groups; therefore, ERb function has primarily been studied by exogenous transfer of ERb expression vectors. ERb is generally considered an antiproliferative mediator with proposed tumorsuppressive activity in ERa-positive cell lines (33) , but proliferative effects have been noted in some circumstances and a bifaceted role of ERb has been suggested (34, 35) . Importantly, we only observed a proliferative function of ERb in the nonadherent malignant mammosphere state and in vivo, not in the adherent state in vitro. Most probably this is a consequence of the low ERb levels in adherent cancer cells. In addition, the sphere-forming capacity was further enhanced by ERb overexpression. Hence, our study also demonstrates the suboptimal capability of adherently growing cell lines to reflect all aspects of tumor biology.
Patient-derived mammospheres are hard to isolate and expand, complicating mechanistic studies. We and others have found that mammospheres generated from MCF7 are to an extent a sufficient complement for mechanistic studies (22) . We observed a marked increase in ERb expression when adherent cells formed mammospheres, correlating with a shift from a high to low ERa/ERb ratio. It has recently been shown that CSCs 
ARTICLE
isolated from several solid tumors display altered energy metabolism and are more glycolytic compared with differentiated tumor cells (27, (36) (37) (38) . Furthermore, upregulation of glycolysis correlates with increased tumor aggressiveness and multidrug resistance (40, 41) . Using whole-transcriptome analysis of MCF7-derived mammospheres, we observed the induced glycolysis process upon stimulation of ERb. This correlated with increased L-lactate concentrations in the growth media from both patient-derived and MCF7 mammospheres, indicating increased anaerobic glycolysis. Ciavardelli et al. reported that BSCs are less dependent on the mitochondrial activity than normal cancer cells and primarily rely on glycolysis for ATP production (26) . Accumulating evidence also suggests that mitochondria are important targets for the actions of estrogens (42, 43) , based on the observation that ERb localizes in mitochondria in various cells (42, (44) (45) (46) (47) (48) (49) . ERb knockdown leads to a mild mitochondrial uncoupling phenotype (50) , while activation of ERb negatively affects oxidative phosphorylation and compromises mitochondrial complexes activity (51) . In adherent breast cancer cells, the introduction of overexpressed ERb causes a strong inhibition of cell proliferation due to the increase of apoptosis through the mitochondrial pathway (52) (53) (54) . Unlike differentiated cancer cells, CSCs are not entirely dependent on mitochondrial oxidative respiration; therefore, ERb as a vulnerability factor for mitochondria might be beneficial for CSC maintenance by enhancing glycolytic shift metabolism. Consistent with these studies, our OCR analyses of MCF7S revealed that DPN stimulation reduced the oxygen consumption rate and could be rescued by the ERb antagonist PHTPP. Furthermore, MCF7S with knockdown of ERb expressed lower levels of glycolytic genes and higher levels of mitochondrial genes compared with the control. Consequently, ERb-mediated impaired mitochondrial function could further aid in the switch toward glycolytic metabolism for ATP production, BSC maintenance, and proliferation.
Based on our xenograft data, we demonstrate that endogenous ERb is proliferative in luminal and triple-negative breast cancer mouse models and can be targeted by PHTPP. We suggest that an ERb antagonist combined with tamoxifen or, alternatively, combined with an aromatase inhibitor should be studied as adjuvant therapy for luminal breast cancer patients, thereby targeting both the more differentiated (mainly ERa (Figure 7 ). But we also suggest that ERb-selective antagonists should be further investigated for patients with ERa-negative tumors, clinically considered hormone independent and not candidates for regular endocrine therapy.
However, there are limitations of our study. First, because of the low expression level of endogenous ERb in cell line-derived spheres, we could not observe massive changes at mRNA level when exploring the function of ERb in BSCs, despite ERb knockdown or stimulation by DPN. There are also important biological restrictions of using cell lines as cancer models, and sophisticated experimental methods should be optimized for the small amount of patient-derived material to further support our data. In addition, we observed that PHTPP is not a complete ERb antagonist and more selective ERb-antagonists should be developed for clinical trials.
Our study highlights the importance of ERb in breast cancer. In contrast to the idea of stem cells as responders to estrogens through paracrine signaling, we propose the novel concept of BSCs as directly estrogen sensitive through ERb, in turn shedding light on the mechanism of estrogen action during breast carcinogenesis. We hope that the identification of stem cell-enriched ERb and its putative ERb antagonist could be utilized as a stem cell-specific therapy to hit breast cancer fully. 
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